Black Diamond Therapeutics ’ BDTX lead clinical-stage program, silevertinib (formerly BDTX-1535), is a brain penetrant, ...

Tagrisso significantly improves overall survival in unresectable stage 3 EGFR-mutant NSCLC, surpassing placebo in the LAURA study. The FDA approved Tagrisso in September 2024 for patients with locally ...

Study results suggest that ctDNA status “is a significant prognostic marker in extracranial EGFR-oligoprogressive disease,” researchers concluded.

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors vs. other agents were tied to a slower eGFR decline for adults with ADPKD and type 2 diabetes.

a LS Means and 95% CI from a random coefficient analysis including available on-treatment eGFR data from Week 6 through Week 110 with multiple imputation; mL/min/1.73m2 per year b LS Means and 95% CI ...

Lubiprostone preserved renal function in stage IIIb-IV CKD patients over 24 weeks without altering uremic toxin levels, suggesting a novel renoprotective mechanism. The trial demonstrated ...